Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058)

NCT05849662 is registered in ClinicalTrials.gov with Therapeutic Advances in Childhood Leukemia Consortium as lead sponsor.

NCT NCT05849662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05849662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058)
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 11, 2024
Completion date
December 31, 2029
Enrollment
58 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cbl syndrome, jcml, jmml, leukemia, juvenile myelomonocytic, neurofibromatosis 1